{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:17:37Z","timestamp":1771867057154,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":3735,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2003,6]]},"DOI":"10.1016\/s0042-6822(03)00152-1","type":"journal-article","created":{"date-parts":[[2003,4,25]],"date-time":"2003-04-25T06:23:44Z","timestamp":1051251824000},"page":"333-342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":156,"title":["The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA"],"prefix":"10.1016","volume":"310","author":[{"given":"Sifang","family":"Zhou","sequence":"first","affiliation":[]},{"given":"Rong","family":"Liu","sequence":"additional","affiliation":[]},{"given":"Bahige M","family":"Baroudy","sequence":"additional","affiliation":[]},{"given":"Bruce A","family":"Malcolm","sequence":"additional","affiliation":[]},{"given":"Gregory R","family":"Reyes","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0042-6822(03)00152-1_BIB1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2000-9505","article-title":"Recovery, persistence, and sequelae in hepatitis C virus infection","volume":"20","author":"Alter","year":"2000","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB2","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1126\/science.290.5498.1972","article-title":"Efficient initiation of HCV RNA replication in cell culture","volume":"290","author":"Blight","year":"2000","journal-title":"Science"},{"key":"10.1016\/S0042-6822(03)00152-1_BIB3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hep.510260231","article-title":"Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C","volume":"26","author":"Bodenheimer","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/S0042-6822(03)00152-1_BIB4","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/00001432-200112000-00015","article-title":"The mechanism of action of ribavirin","volume":"14","author":"Cameron","year":"2001","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB5","doi-asserted-by":"crossref","first-page":"27286","DOI":"10.1016\/S0021-9258(19)74247-1","article-title":"Characterization of human type I and type II IMP dehydrogenases","volume":"268","author":"Carr","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB6","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1128\/AAC.33.11.2009","article-title":"Mechanism of La Crosse virus inhibition by ribavirin","volume":"33","author":"Cassidy","year":"1989","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/S0042-6822(03)00152-1_BIB7","doi-asserted-by":"crossref","first-page":"9847","DOI":"10.1073\/pnas.171319698","article-title":"Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system","volume":"98","author":"Chung","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0042-6822(03)00152-1_BIB8","doi-asserted-by":"crossref","first-page":"8505","DOI":"10.1128\/JVI.76.17.8505-8517.2002","article-title":"Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system","volume":"76","author":"Contreras","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB9","doi-asserted-by":"crossref","first-page":"6895","DOI":"10.1073\/pnas.111085598","article-title":"RNA virus error catastrophe","volume":"98","author":"Crotty","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0042-6822(03)00152-1_BIB10","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/82191","article-title":"The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen","volume":"6","author":"Crotty","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB11","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM199811193392102","article-title":"Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group","volume":"339","author":"Davis","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB12","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1128\/AAC.35.4.679","article-title":"Antiviral activities of 5-ethynyl-1-beta-d-ribofuranosylimidazole-4-carboxamide and related compounds","volume":"35","author":"De Clercq","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB13","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/viro.2000.0320","article-title":"Viruses at the edge of adaptation","volume":"270","author":"Domingo","year":"2000","journal-title":"Virology"},{"key":"10.1016\/S0042-6822(03)00152-1_BIB14","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0168-8278(96)80225-X","article-title":"Ribavirin treatment for patients with chronic hepatitis C","volume":"25","author":"Dusheiko","year":"1996","journal-title":"J. Hepatol."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB15","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/BF00623322","article-title":"Selforganization of matter and the evolution of biological macromolecules","volume":"58","author":"Eigen","year":"1971","journal-title":"Naturwissenschaften"},{"key":"10.1016\/S0042-6822(03)00152-1_BIB16","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1128\/AAC.11.6.946","article-title":"Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate","volume":"11","author":"Eriksson","year":"1977","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB17","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"10.1016\/S0042-6822(03)00152-1_BIB18","first-page":"17","article-title":"The clinical pharmacology of ribavirin","volume":"19","author":"Glue","year":"1999","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB19","first-page":"12938","article-title":"From the cover","volume":"99","author":"Grande-Perez","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0042-6822(03)00152-1_BIB20","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1128\/jvi.64.8.3960-3962.1990","article-title":"Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis","volume":"64","author":"Holland","year":"1990","journal-title":"J. Virol."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.1365-2125.1998.00836.x","article-title":"Ribavirin and interferon alfa-2b in chronic hepatitis C","volume":"46","author":"Khakoo","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB22","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1128\/JVI.75.10.4614-4624.2001","article-title":"Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations","volume":"75","author":"Krieger","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB23","doi-asserted-by":"crossref","first-page":"8074","DOI":"10.1128\/JVI.75.17.8074-8081.2001","article-title":"Ribavirin induces error prone replication of GBV-B in primary tamarin hepatocytes","volume":"75","author":"Lanford","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB24","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1128\/JVI.77.2.1092-1104.2003","article-title":"Antiviral effect and virus\u2013host interactions in response to alpha interferon, gamma interferon, poly(I)\u2013poly(C), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons","volume":"77","author":"Lanford","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C virus infection","volume":"345","author":"Lauer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB26","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1073\/pnas.96.4.1492","article-title":"Lethal mutagenesis of HIV with mutagenic nucleoside analogs","volume":"96","author":"Loeb","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0042-6822(03)00152-1_BIB27","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science"},{"key":"10.1016\/S0042-6822(03)00152-1_BIB28","doi-asserted-by":"crossref","first-page":"46094","DOI":"10.1074\/jbc.C100349200","article-title":"Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin","volume":"276","author":"Maag","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0042-6822(81)90060-X","article-title":"Inhibitors of IMP dehydrogenase prevent Sindbis virus replication and reduce GTP levels in Aedes albopictus cells","volume":"110","author":"Malinowski","year":"1981","journal-title":"Virology"},{"key":"10.1016\/S0042-6822(03)00152-1_BIB30","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1128\/AAC.44.4.859-866.2000","article-title":"Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497","volume":"44","author":"Markland","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB31","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchison","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB32","doi-asserted-by":"crossref","first-page":"9723","DOI":"10.1128\/JVI.75.20.9723-9730.2001","article-title":"Efficient virus extinction by combinations of a mutagen and antiviral inhibitors","volume":"75","author":"Pariente","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB33","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1128\/JVI.75.3.1252-1264.2001","article-title":"Characterization of cell lines carrying self-replicating hepatitis C virus RNAs","volume":"75","author":"Pietschmann","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB34","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1128\/AAC.43.10.2451","article-title":"Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology","volume":"43","author":"Preston","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB35","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0042-6822(89)90413-3","article-title":"Studies on the mechanism of the antiviral activity of ribavirin against reovirus","volume":"168","author":"Rankin","year":"1989","journal-title":"Virology"},{"key":"10.1016\/S0042-6822(03)00152-1_BIB36","first-page":"651","article-title":"Ribavirin","volume":"4","author":"Reyes","year":"2001","journal-title":"Curr. Opin. Drug Discov. Dev."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB37","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1126\/science.177.4050.705","article-title":"Broad-spectrum antiviral activity of Virazole","volume":"177","author":"Sidwell","year":"1972","journal-title":"Science"},{"key":"10.1016\/S0042-6822(03)00152-1_BIB38","doi-asserted-by":"crossref","first-page":"8316","DOI":"10.1128\/JVI.74.18.8316-8323.2000","article-title":"Response of foot-and-mouth disease virus to increased mutagenesis","volume":"74","author":"Sierra","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB39","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1073\/pnas.70.4.1174","article-title":"Mechanisms of action of 1-\u03b2-d-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole) a new broad spectrum antiviral agent","volume":"70","author":"Streeter","year":"1973","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0042-6822(03)00152-1_BIB40","first-page":"261","article-title":"Mechanisms of action of ribavirin in antiviral therapies","volume":"12","author":"Tam","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB41","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1128\/AAC.32.4.492","article-title":"Effect of phosphorylated ribavirin on vesicular stomatitis virus transcription","volume":"32","author":"Toltzis","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-2000-9506","article-title":"Epidemiology of hepatitis C","volume":"20","author":"Wasley","year":"2000","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/S0042-6822(03)00152-1_BIB43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0166-3542(85)90012-9","article-title":"Mode of action of ribavirin","volume":"5","author":"Wray","year":"1985","journal-title":"Antiviral Res."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682203001521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682203001521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T23:21:02Z","timestamp":1758583262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682203001521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["S0042682203001521"],"URL":"https:\/\/doi.org\/10.1016\/s0042-6822(03)00152-1","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2003,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0042-6822(03)00152-1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 Elsevier Science (USA). All rights reserved.","name":"copyright","label":"Copyright"}]}}